Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Avalyn Pharma Q3 2026 Results: Net Loss of $29.7M, Loss Widens

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-29.7-23.6
EPS (diluted, $ a share)$-0.67$-20.34

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AVLN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Avalyn Pharma Inc.: key numbers

Share price
$29.76Close, Nov 16
Market cap
$1.32B
Shares outstanding
44.33MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Avalyn Pharma Inc.

All →
11:36 AM ET Form 4
Insider Selling

Avalyn Pharma 10% Owner Fmr LLC Sells $6.7M of Stock

Fmr LLC, 10% Owner, sold 228,454 shares of Avalyn Pharma Inc. at $29.06 to $30.28 a share (average $29.33) in 4 transactions, worth $6.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,056,081 (-2.3%).

Value
$6.7M
Shares
228,454
Average price
$29.33
Role
10% Owner
Holding change
-2.3%
Trade date
Nov 9, 2026 to Nov 10, 2026
8:08 AM ET 8-K
Financial Results

Avalyn Pharma Financial Results

Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.

Term
Q3 2026

“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”

Lyn Baranowski, Chief Executive Officer of Avalyn

“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”

Lyn Baranowski, Chief Executive Officer of Avalyn
4:13 PM ET 8-K
Leadership Change

Avalyn Pharma Leadership Change

Avalyn Pharma Inc. appointed Robert Meyer, M.D. to its Board of Directors as a Class II director, effective September 15, 2026. Dr. Meyer, a former FDA director and Merck executive, brings extensive regulatory and clinical experience to the board. He will receive an annual cash retainer of $40,000 and an initial grant of options to purchase 31,182 shares of common stock.

Counterparty
Robert Meyer, M.D.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.